Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2006 1
2007 1
2008 1
2009 1
2010 2
2011 3
2012 3
2014 1
2015 1
2016 3
2017 3
2018 2
2019 4
2020 2
2022 2
2023 3
2024 5
2025 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

37 results

Results by year

Filters applied: . Clear all
Page 1
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, Baeres FMM, Idorn T, Bosch-Traberg H, Lausvig NL, Pratley R; FLOW Trial Committees and Investigators. Perkovic V, et al. N Engl J Med. 2024 Jul 11;391(2):109-121. doi: 10.1056/NEJMoa2403347. Epub 2024 May 24. N Engl J Med. 2024. PMID: 38785209 Clinical Trial.
Comparing advanced hybrid closed loop therapy and standard insulin therapy in pregnant women with type 1 diabetes (CRISTAL): a parallel-group, open-label, randomised controlled trial.
Benhalima K, Beunen K, Van Wilder N, Ballaux D, Vanhaverbeke G, Taes Y, Aers XP, Nobels F, Marlier J, Lee D, Cuypers J, Preumont V, Siegelaar SE, Painter RC, Laenen A, Gillard P, Mathieu C. Benhalima K, et al. Among authors: preumont v. Lancet Diabetes Endocrinol. 2024 Jun;12(6):390-403. doi: 10.1016/S2213-8587(24)00089-5. Epub 2024 Apr 30. Lancet Diabetes Endocrinol. 2024. PMID: 38697182 Clinical Trial.
Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial.
Pieber TR, Bode B, Mertens A, Cho YM, Christiansen E, Hertz CL, Wallenstein SOR, Buse JB; PIONEER 7 investigators. Pieber TR, et al. Lancet Diabetes Endocrinol. 2019 Jul;7(7):528-539. doi: 10.1016/S2213-8587(19)30194-9. Epub 2019 Jun 9. Lancet Diabetes Endocrinol. 2019. PMID: 31189520 Clinical Trial.
Advanced Hybrid Closed-Loop Therapy Compared With Standard Insulin Therapy Intrapartum and Early Postpartum in Women With Type 1 Diabetes: A Secondary Observational Analysis From the CRISTAL Randomized Controlled Trial.
Beunen K, Gillard P, Van Wilder N, Ballaux D, Vanhaverbeke G, Taes Y, Aers XP, Nobels F, Van Huffel L, Marlier J, Lee D, Cuypers J, Preumont V, Siegelaar SE, Painter RC, Laenen A, Mathieu C, Benhalima K. Beunen K, et al. Among authors: preumont v. Diabetes Care. 2024 Nov 1;47(11):2002-2011. doi: 10.2337/dc24-1320. Diabetes Care. 2024. PMID: 39331059 Clinical Trial.
Effects of Semaglutide With or Without Concomitant Mineralocorticoid Receptor Antagonist Use in Participants With Type 2 Diabetes and Chronic Kidney Disease: A FLOW Trial Prespecified Secondary Analysis.
Rossing P, Bakris G, Perkovic V, Pratley R, Tuttle KR, Mahaffey KW, Idorn T, Belmar N, Bosch-Traberg H, Rasmussen S, Busch RS, Schmieder RE, Gillard P, Mann JFE; FLOW Investigator Group. Rossing P, et al. Diabetes Care. 2025 Jul 29:dc250472. doi: 10.2337/dc25-0472. Online ahead of print. Diabetes Care. 2025. PMID: 40730031
Hypoglycaemia revealing heterozygous insulin receptor mutations.
Preumont V, Feincoeur C, Lascols O, Courtillot C, Touraine P, Maiter D, Vigouroux C. Preumont V, et al. Diabetes Metab. 2017 Feb;43(1):95-96. doi: 10.1016/j.diabet.2016.07.001. Epub 2016 Jul 26. Diabetes Metab. 2017. PMID: 27474196 Free PMC article. No abstract available.
37 results